The use of cBioPortal revealed that genetic modifications of the ten genes in the PHLDA1, PHLDA2, and PHLDA3 signatures primarily occurred in bladder and lung cancers, with alteration frequencies ranging between 35.54%, 26.11%, and 43.17%, respectively. This evidence concerns the gene PHLDA3 and lung cancer.